RYBREVANT® Access and Reimbursement Guide Overview

Key Takeaways

• RYBREVANT® is indicated for specific NSCLC mutations, including EGFR exon 19 deletions, exon 21 L858R substitution mutations, and exon 20 insertion mutations.
• Biomarker testing is essential for patient selection, with FDA-approved tests recommended to determine eligibility for RYBREVANT® treatment.
• Reimbursement policies for biomarker testing and RYBREVANT® vary by payer and plan, including Medicare, Medicare Advantage, Commercial, and Medicaid.
• Consulting payer organizations is recommended to obtain the most up-to-date information on reimbursement policies, prior authorization requirements, and patient cost-sharing.
• Important safety information regarding RYBREVANT®, including warnings and precautions, is included in the guide.

What does this document cover?

The RYBREVANT® Access and Reimbursement Guide, published by asset.jnjwithme.com, provides comprehensive information on RYBREVANT®'s indications, coding, biomarker testing, and reimbursement strategies to facilitate patient access. The guide includes coding information, a list of specialty distributors, and important product information.

Why it matters for pharma teams

Understanding reimbursement processes is critical for ensuring patient access to RYBREVANT®, impacting commercial success and regulatory compliance.